ArticleCancer research2018
Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV
Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Mucosal immunity: mechanism and application in cancer immunotherapy.Journal of hematology & oncology · 2026Review
- Immunological dynamics in orthotopic compared with subcutaneous murine models of HPV-positive oropharyngeal cancer.Disease models & mechanisms · 2025Article
- Trends in immunotherapy for oral squamous cell carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Review
- Targeted inhibition of Aurora kinase A promotes immune checkpoint inhibition efficacy in human papillomavirus-driven cancers.Journal for immunotherapy of cancer · 2025Article
- Viral vector-based therapeutic HPV vaccines.Clinical and experimental medicine · 2024Review
- Immunity from NK Cell Subsets Is Important for Vaccine-Mediated Protection in HPV+ Cancers.Vaccines · 2024Article
- Production of recombinant HPV11/16 E6/E7-MBP-HisVirology journal · 2024Article
- Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.Cancer cell international · 2022Review
- Head and Neck Squamous Cell Carcinoma: Risk Factors, Molecular Alterations, Immunology and Peptide Vaccines.International journal of peptide research and therapeutics · 2022Review
- Review
- Novel Antigenic Targets of HPV Therapeutic Vaccines.Vaccines · 2021Review
- The Use of the Antigenic Protein HPV6 L1 to Induce the Synthesis of Interferon, CD4 and CD8 T Lymphocytes, and Granzyme B in Blood and Splenocytes of Mice in Order to Develop a Broad Vaccine against Anogenital Papillomatoses.Doklady. Biochemistry and biophysics · 2021Article
- The Potential of Immune Checkpoint Blockade in Cervical Cancer: Can Combinatorial Regimens Maximize Response? A Review of the Literature.Current treatment options in oncology · 2020Review
- Human Papillomavirus Vaccines: An Updated Review.Vaccines · 2020Review
- Development of HPVBiotechnology letters · 2020Article
- Cervical Cancer: Emerging Immune Landscape and Treatment.OncoTargets and therapy · 2020Review
- Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy.Frontiers in immunology · 2020Review
- Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPVJournal for immunotherapy of cancer · 2019Article
- The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer.Cancer treatment reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
High-risk human papillomavirus (HPV)-associated squamous cell carcinomas of the oropharynx (SCCOP) are among the fastest growing cancers. After standard-of-care treatment, however, patients with HPV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.